FIM
AVDL

Freedom Investment Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Freedom Investment Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,022
Closed -$105K – 436
2013
Q3 		$105K Buy
16,022
+3,910
+32% +$24K 0.03% 360
2013
Q2 		$74K Buy
+12,112
New +$62.6K 0.03% 324

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Freedom Investment Management's AVDL Position: Q4 2013 in Review

Freedom Investment Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2013, closing a stake of 16,022 shares — an estimated $105K sold.

Freedom Investment Management first reported a position in AVDL in Q2 2013 and held it in 2 quarters. The position peaked at $105K in Q3 2013. 35 funds tracked by Wall St. Rank hold AVDL as of Q4 2013.

  • Freedom Investment Management reported no remaining Avadel Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Freedom Investment Management sold 16,022 Avadel Pharmaceuticals shares in Q4 2013, an estimated $105K.
  • Freedom Investment Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Freedom Investment Management's Avadel Pharmaceuticals position peaked at $105K in Q3 2013.
  • 35 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2013.

Based on Freedom Investment Management's 13F filing for Q4 2013, filed 12 Feb 2014.